Healthcare / BiotechnologyNasdaqCM
$0.78
+0.01 (+1.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.2M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$25M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-400.1%
↓Gross Margin
67.0%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-26.6%
FCF CAGR
—
FCF margin
-1604.7%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.2M · net income $-22.7M · FCF $-19.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $1.2M | $1.2M | $2.4M | $709000.00 | $1.2M | $1.3M | $5.6M |
| Net Income | $-22.7M | $-22.7M | $-16.0M | $-21.4M | $-18.8M | $-17.0M | $-3.7M |
| EBITDA | $-22.1M | $-22.1M | $-15.6M | $-20.1M | $-17.1M | $-17.5M | $-3.8M |
| EPS | — | — | -2.62 | -10.22 | -9.00 | -9.00 | — |
| Gross Margin | 67.0% | 67.0% | 78.8% | 31.2% | 40.7% | 45.2% | 32.4% |
| Operating Margin | -1942.2% | -1942.2% | -690.7% | -2966.0% | -1476.5% | -1336.6% | -67.1% |
| Net Margin | -1893.6% | -1893.6% | -667.8% | -3020.2% | -1541.3% | -1305.1% | -66.1% |
| Balance Sheet | |||||||
| Debt/Equity | 0.15 | 0.15 | 0.07 | 0.30 | 0.13 | — | 0.16 |
| Current Ratio | 3.88 | 3.88 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-19.2M | $-19.2M | $-14.9M | $-19.7M | $-14.8M | $-10.0M | $-2.5M |
| Returns | |||||||
| ROE | -400.1% | -400.1% | -73.0% | -317.7% | -91.9% | -45.5% | -190.1% |
| Valuation | |||||||
| P/B | 3.15 | 3.15 | 0.82 | 4.16 | 3.65 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -49.9% | -49.9% | 237.4% | -42.0% | — | -76.8% | — |
| EPS Growth | — | — | 74.4% | -13.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.62 → n/d
Residual
-37.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.